Insider Transactions in Q1 2025 at Exact Sciences Corp (EXAS)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 20
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
1,531
-11.24%
|
$76,550
$50.48 P/Share
|
|
Feb 20
2025
|
James Herriott SVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
3,324
+19.62%
|
-
|
|
Feb 20
2025
|
Sarah Condella EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,214
-2.82%
|
$110,700
$50.48 P/Share
|
|
Feb 20
2025
|
Sarah Condella EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
4,805
+5.76%
|
-
|
|
Feb 20
2025
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
2,437
-13.3%
|
$121,850
$50.48 P/Share
|
|
Feb 20
2025
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
4,805
+20.77%
|
-
|
|
Feb 20
2025
|
Jacob A Orville EVP, GM, Screening |
SELL
Payment of exercise price or tax liability
|
Direct |
2,225
-10.9%
|
$111,250
$50.48 P/Share
|
|
Feb 20
2025
|
Jacob A Orville EVP, GM, Screening |
BUY
Grant, award, or other acquisition
|
Direct |
4,805
+19.06%
|
-
|
|
Feb 20
2025
|
Kevin T Conroy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,140
-1.87%
|
$1,057,000
$50.48 P/Share
|
|
Feb 20
2025
|
Kevin T Conroy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,044
+4.08%
|
-
|
|
Feb 19
2025
|
James Herriott SVP, General Counsel & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-4.04%
|
$21,217
$49.63 P/Share
|
|
Feb 19
2025
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
865
+7.46%
|
-
|
|
Feb 19
2025
|
Sarah Condella EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,107
-1.48%
|
$54,243
$49.63 P/Share
|
|
Feb 19
2025
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+2.92%
|
-
|
|
Feb 19
2025
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
968
-6.68%
|
$47,432
$49.63 P/Share
|
|
Feb 19
2025
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,729
+10.66%
|
-
|
|
Feb 19
2025
|
Jacob A Orville EVP, GM, Screening |
SELL
Payment of exercise price or tax liability
|
Direct |
1,086
-6.51%
|
$53,214
$49.63 P/Share
|
|
Feb 19
2025
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+11.87%
|
-
|
|
Feb 19
2025
|
D Scott Coward |
SELL
Payment of exercise price or tax liability
|
Direct |
667
-1.26%
|
$32,683
$49.63 P/Share
|
|
Feb 19
2025
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+4.08%
|
-
|
|
Feb 19
2025
|
Kevin T Conroy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,271
-0.3%
|
$160,279
$49.63 P/Share
|
|
Feb 19
2025
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,374
+0.95%
|
-
|
|
Jan 02
2025
|
Kimberly J Popovits |
BUY
Grant, award, or other acquisition
|
Direct |
6,387
+50.0%
|
-
|